ELIXF (Elixxer) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Elixxer EBITDA Margin %?

Elixxer ELIXF EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Elixxer ranks worse than 104711.94% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Elixxer's EBITDA for the three months ended in Dec. 2025 was $-0.97 Mil. Elixxer's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Elixxer's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Elixxer  (OTCPK:ELIXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Elixxer EBITDA Margin % Related Terms

Elixxer EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Elixxer's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elixxer EBITDA Margin % Chart

Elixxer Annual Data
Trend Jun15 Jun16 Sep17 Sep18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Elixxer Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ELIXF vs ZTS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elixxer's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elixxer EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elixxer's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Elixxer's EBITDA Margin % falls into.


Elixxer EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Elixxer's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.212/0
= %

Elixxer's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.966/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Elixxer (ELIXF) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elixxer and its competitors. According to the industry distribution chart, Elixxer ranks #999999 out of 955 companies in the Drug Manufacturers industry.
Is Elixxer's EBITDA Margin % too high?
Elixxer's current EBITDA Margin % is 0.00%. Based on the distribution chart, Elixxer ranks #999999 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Elixxer's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Elixxer ranks #999999 out of 955 companies for EBITDA Margin %. This places Elixxer in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elixxer and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elixxer's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixxer stock overvalued right now?
Elixxer (ELIXF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Elixxer (ELIXF), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elixxer Business Description

Other Exchanges ELXR.H:Canada
Address 200 Bay Street, Suite 3240, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Elixxer Ltd is a Canada-based cannabis investment firm in the legal cannabis market. It invests in cannabis-related businesses that are fully licensed for the cultivation, production, and sale of cannabis and cannabis-derived products.